RG 7356

Drug Profile

RG 7356

Alternative Names: RG-7356; RO-5429083

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chugai Biopharmaceuticals; Roche
  • Developer Roche
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; CD44 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 01 Feb 2015 Roche completes a phase I trial for Acute myeloid leukaemia in France, Germany and Italy (NCT01641250)
  • 30 Jan 2014 Discontinued - Phase-I for Acute myeloid leukaemia in Italy (IV)
  • 30 Jan 2014 Discontinued - Phase-I for Solid tumours (late-stage disease, metastatic disease) in France and the Netherlands (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top